Surgery Partners' Q3 Loss Narrows To $21 Mln; HealthSpan Merger Worth $6 Bln To Close In Q1 '27
Surgery Partners (SGRY) reported a Q3 net loss of $21.1M, down from $22.7M YoY, on revenues of $815.3M, a 0.8% decrease. Adjusted EBITDA was $132.7M. The company announced a revised merger agreement with HealthSpan, now valued at $6B, to close in Q1 2027. SGRY stock was up 1.06% at close.
How this was made
The 30-second read
Why it matters
The merger premium and cash component provide a clear upside catalyst, while the modest loss narrowing offers limited downside.
Market read
Primary M&A disclosure with a multi‑billion‑dollar valuation, likely to move SGRY stock and influence sector peers.
What to watch
Regulatory approval risk and integration challenges could delay value realization.
Background
Surgery Partners reported Q3 loss narrowing to $21 M and modest revenue decline, then announced an amended $6 B all‑cash merger with HealthSpan, increasing the cash consideration to $25 per share.
Ticker impact
Surgery Partners disclosed a revised all‑cash merger with HealthSpan valued at $6 billion, raising the per‑share consideration to $25 and extending the close to Q1 2027.
likely upward pressure as investors value the $25 cash offer
Merger announcement with a sizable premium is a material catalyst; the stock already rose modestly on the news.
Market effects
Consolidation trend in outpatient surgery centers may pressure peers' valuations.
U.S. healthcare services sector sees modest positive sentiment.
Limited to U.S. healthcare investors; no broader macro effect.
Counterpoint
If the competing bid materializes, the deal could be renegotiated or collapse, exposing downside risk.
Key entities
- companySurgery Partners Inc.
U.S. outpatient surgery center operator (ticker SGRY).
- companyHealthSpan Partners
Acquirer in the all‑cash transaction.
